Parallel Tracking i-biomarkerT Development with Drug Development for Maximum Benefit
2,403 views
|
February 18, 2015
Molecular imaging is increasingly being used to support decision making in early-stage drug development, particularly in the CNS. Providing invaluable information on the so-called ‘three pillars of drug survival’, namely tissue delivery, target engagement and pharmacological effect, it can be seen as a kind of precision pharmacology However, a lack of appreciation of when and how to use imaging and a lack of suitable tools means imaging is often an afterthought and employed in a post mortem of drug failure. Timely development of imaging biomarkers will ensure the full translational value of this technology can be realised This talk will illustrate, with case studies, how appropriate and timely use of imaging biomarkers can significantly reduce the risk, cost and time of drug development. Key benefits:
DiagnosticsProteomics and Metabolomics
